Perceptive Advisors reports 20.03% stake in XTL Biopharmaceuticals

By Jennifer Chiou

New York, July 18 - XTL Biopharmaceuticals Ltd. investors led by Perceptive Advisors LLC, Joseph Edelman, Michael Cho and Scott Bradley reported a 20.03% stake in XTL, according to a schedule 13-D/A filing with the Securities and Exchange Commission.

The reporting persons own 58,618,420 shares of the New York-based developer and seller of therapies for hepatitis C.

They acquired the shares in various transactions between Jan. 15, 2008 and March 14 at prices between $2.8838 and $4.0127 per share.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.